Three major drug companies are reporting a medication shortage for the common child antibiotic, amoxicillin.
The companies are worried about supply issues right now.
The three companies showing concern are Hikma Pharmaceuticals, Teva Pharmaceutical Industries and Sandoz. Sandoz makes the generic medications for Novartis.
This is dangerous because amoxicillin is commonly used to treat bacterial infections in children.
Why an amoxicillin medication shortage is bad
The antibiotic comes in the form of a capsule, tablet, chewable tablet, and liquid which can all be taken by mouth.
Most shortages are happening with the liquid form, which impacts young children.
According to My Twin Tiers, as of Oct. 25, the University of Utah’s drug information service has reported the shortages.
Right now it appears that 14 amoxicillin products from Hikma Pharmaceuticals and 9 from Teva are all facing shortages. 16 are listed for Sandoz.
These antibiotics are commonly used for ear infections in children. They can also be used for bacterial sinus and throat infections. There are other medications that can be used.
The FDA does not consider this to be a medication shortage
While the FDA has stated it’s aware of some intermittent supply interruptions of amoxicillin products, it doesn’t consider it to mean amoxicillin is facing a shortage.
The FDA is working with approved manufacturers.
It isn’t considered a shortage by the FDA because there is at least one company that can fully supply the market demand.
Hikma has enough to fulfill current customers orders, but will be limiting future orders.
Sandoz has shared that there’s been an increase in demand for the medication.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected]